Impact of three interactive Texas state regulatory programs to decrease ambient air toxic levels

Science communication on the public health risks of air pollution: a computational scoping review from 1958 to 2022

BACKGROUND

Air pollutants are a health risk for the entire population. Particulate matter (PM) including the smallest fraction, ultra-fine particles (UFP), therefore continue to be the focus of scientific research in this area. To protect the population from the harmful effects of exposure to PM, communication and information of research results are of special relevance as individuals with heightened awareness of the harms of poor air quality are more likely to take action to improve their exposure.

METHODS

We conducted a scoping review of the scientific literature on science communication of public health information about risks associated with air pollutants to generate an initial over-view of existing research in this field. We searched the PubMed and Scopus databases and analyzed the data using a structured topic modeling (STM) approach.

RESULTS

The existing scientific literature dates back to 1958 but increases significantly from the 1990s onwards. Publications are mainly found in the discipline of environmental research and are primarily concerned with health effects. It is often stated that adequate communication of the results to the public would be important, but specific approaches are rare. Overall, the topic of risk communication seems to be underrepresented for both air pollutants and UFP.

CONCLUSIONS

To protect public health, it is important to conduct more intensive science and risk communication related to scientific findings on the risks of air pollutants. For adequate communication and information, further research is needed to provide specific approaches that also involve the affected population and take different target groups into account. In addition, the effectiveness of communication efforts should also be analyzed.

Assessment of chronic inhalation non-cancer toxicity for diethylamine

A non-cancer inhalation chronic toxicity assessment for diethylamine (DEA, CAS number 109-89-7) was conducted by the Texas Commission on Environmental Quality. A chronic Reference Value (ReV) was determined based on a high-quality study conducted in mice and rats by the National Toxicology Program. Chronic inhalation ReVs are health-based exposure concentrations used in assessing health risks of long-term (i.e. lifetime) chemical exposure. DEA is used industrially as an organic intermediate to produce corrosion inhibitors, and is widely used in rubber, pharmaceuticals, resins, pesticides, insect repellants, dye processing and as a polymerization inhibitor. Although systemic effects have been noted at higher concentrations, DEA acts primarily as a respiratory irritant with effects occurring in the upper respiratory tract. Rats were exposed to 0, 31, 62.5 and 125 ppm DEA and mice to 0, 16, 31 and 62.5 ppm DEA for 6 h/day, 5 days/week for 105 weeks. Mice were slightly more sensitive than rats. The critical effect identified in mice was hyperostosis in the turbinates although DEA caused a number of other non-neoplatic lesions. Dose–response data were suitable to benchmark concentration (BMC) modeling. The human equivalent point of departure (POD_HEC) was calculated from the 95% lower limit of the BMC(10) using default duration and animal-to-human dosimetric adjustments. Total uncertainty factors of 90 were applied to the POD_HEC to account for variation in sensitivity within the human population, toxicodynamic differences between mice and humans, and database uncertainty. The chronic ReV for DEA is 11 ppb (33 µg/m³).

Use of In Vivo and In Vitro Data to Derive a Chronic Reference Value for Crotonaldehyde Based on Relative Potency to Acrolein

The Texas Commission on Environmental Quality (TCEQ) conducted a chronic inhalation noncancer toxicity assessment for crotonaldehyde (CRO). Since there were limited toxicity data for CRO, a reference value (ReV) was derived using a relative potency factor (RPF) approach with acrolein as the index chemical. Both CRO and acrolein are α,β-unsaturated carbonyls and share common steps in their mode of action (MOA). Only studies that investigated the effects of CRO and acrolein in the same study were used to calculate a CRO:acrolein RPF. In vivo findings measuring both 50% respiratory depression in rats and two species of mice and subcutaneous 50% lethality in rats and mice were used to calculate an RPF of 3 (rounded to one significant figure). In vitro data were useful to compare the MOA of CRO and acrolein and to support the RPF determined using in vivo data. In vitro cell culture studies investigating cytotoxicity in normal human lung fibroblast cultures using the propidium iodide cytotoxicity assay and in mouse lymphocyte cultures using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay were used to calculate an in vitro RPF of 3, which supports the in vivo RPF. The chronic ReV for acrolein of 1.2 ppb derived by TCEQ was multiplied by the RPF of 3 to calculate the ReV for CRO of 3.6 ppb (10 μg/m(3)). The ReV for CRO was developed to protect the general public from adverse health effects from chronic exposure to CRO in ambient air.

Development of a chronic inhalation reference value for hexamethylenediamine using an exposure model based on the dihydrochloride salt

The Texas Commission on Environmental Quality has developed a chronic inhalation Reference Value (ReV) for hexamethylenediamine (HMDA, CAS 124-09-4) based on respiratory effects identified in an animal study. HMDA is used in the fiber and plastics industry as an intermediate in the production of nylon, high-strength resins and polyamide adhesives. As a toxicant, HMDA acts primarily as a respiratory irritant with effects occurring in the upper respiratory tract, although systemic effects have been noted at higher concentrations. ReVs are chemical-specific air concentrations derived to protect human health. Acute and chronic ReVs were developed for HDMA based on an inhalation study conducted by the National Toxicology Program (NTP), which used the salt of HMDA, hexamethylenediamine dihydrochloride (HDDC, CAS 6055-52-3). For the chronic evaluation, rats and mice were exposed to 0, 1.6, 5, 16, 50 and 160 mg HDDC/m(3) for 13 weeks. The critical effect identified for the most sensitive species was hyaline degeneration in the olfactory epithelium in mice. The data provided in this study were suitable to benchmark concentration (BMC) modeling. Dosimetric adjustments using the rat and mouse Multiple-Path Particle Dosimetry Model (version 3.0) were made to the 95% lower limit of the BMC(10) to determine the human equivalent point of departure. Uncertainty factors were applied to account for variation in sensitivity within the human population, toxicodynamic differences between mice and humans, and use of a subchronic study. The ReV was initially calculated for HDDC and then adjusted for HMDA. The chronic ReV is 1.8 µg/m(3) for respirable HMDA ≤ 10 µm in diameter.